



# woman2

# **HOW TO COMPLETE THE CRF – OUTCOME DATA**

Protocol number: ISRCTN62396133 Version 1.0; Date 05 April 2019

# **CONTENTS OF THE CRF BOOKLET**

- Each participant will have a Case Report Form (CRF) booklet.
- A CRF booklet contains:
  - Baseline Form
  - Outcome Form
  - Adverse Event Form

This presentation will focus on the **Outcome Form** and the **Adverse Event Form:** 


• Completion should start after the participant has been randomised.

PATIENT INITIALS	HOSPITAL NAME SCREENING ID Lost NUMBER - SITE ID Patient Screening #
Ţ	Case Report Forms
FULL TITLE OF STUDY	Tranexamic acid for reducing postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo controlled trial
SHORT TITLE	World Maternal Antifibrinolytic Trial-2
TRIAL ACRONYM	WOMAN-2
	WOMAN-2 ISRCTN62396133
TRIAL ACRONYM	
TRIAL ACRONYM PROTOCOL NUMBER CLINICALTRIALS.GOV ID	ISRCTN62396133
TRIAL ACRONYM PROTOCOL NUMBER CLINICAL TRIALS.GOV ID DO NOT	ISRCTN62396133 NCT03475342

## **OUTCOME DATA COLLECTION**

	What?	When
Outcome form (Part 1): Sections A – C	<ul> <li>About the patient</li> <li>Interventions given</li> <li>Postpartum haemorrhage diagnosis</li> </ul>	At 24 hours after randomisation, discharge from hospital or death – whichever occurs first
Outcome form (Part 2): Sections D – G	<ul> <li>Patient reported outcomes</li> <li>Management</li> <li>Complications</li> <li>Status of baby/ies</li> </ul>	At 42 days after randomisation, discharge from hospital or death – whichever occurs first
Adverse event form	<ul> <li>If in hospital: any <u>untoward</u> medical event that occurs up to 42 days after randomisation and is NOT collected on the outcome form</li> <li>If discharged from hospital: any <u>untoward</u> medical event, which develops up to 42 days after randomisation (including those listed on the outcome forms)</li> </ul>	that fulfils the Adverse Event definition as per the protocol, up to 42 days after randomisation

# WHEN TO COMPLETE THE OUTCOME FORMS – example scenarios



**#** hours after randomisation

- Example 1: Participant A If a woman is discharged at 6 hours (or anytime before 24 hours) after randomisation complete all of the outcome form (Parts 1 and 2) at the point of discharge
- Example 2: Participant B dies 22 hours (or anytime before 24 hours) after randomisation complete all of the outcome form at the point of death. Questionnaire and walk test not applicable
- Example 3: Participant C discharged 36 hours (or anytime after 24 hours and up to day 42) after randomisation - complete Part 1 at 24 hours after randomisation. Complete Part 2 at point of discharge

#### Enter all outcome data into the trial database within 24 hrs of <u>both</u> forms being completed

# **OUTCOME FORM (Part 1):** SECTIONS A - C

WHEN: At 24 hours following randomisation, discharge or death – whichever comes first

- Complete Section A:
  - Using the HemoCue analyser provided, carry out a haemoglobin test:
    - Take a drop of blood from the participant's finger, fill the microcuvette, put it in the HemoCue holder, close and wait for 15 60 seconds for the results.
- Complete Sections B:
  - Includes information about interventions given during delivery.
- Complete Section C:
  - Includes information on postpartum haemorrhage (PPH) diagnosis.
- Obtain data from medical records where possible, otherwise speak to clinical team.





# OUTCOME FORM (Part 2): SECTIONS D – G

WHEN: At 42 days following randomisation, discharge or death – whichever comes first

- Complete Sections D G:
  - Section D: Patient outcome
  - Section E: Patient Management
  - Section F: Complications
  - Section G: Status of baby/ies
- Obtain data from medical records.

complete sections	'D TO G' A		IOSPITA									
SECTION D - PATIENT ( 49. Written consent obtained fi patient? (circle one) 49a. If no written consent, give		YES NO	T	waman2		SCREENII	NG ID MBER -					
49a. reason why Q 50 Status (If patient died, c	omplete se	ction 50.1. If patient al	live, com	SECTION F - COMPLICATIO	NS							
50.1 DIED IN HOSPITAL (circle ont)	YE	50	2 WOMA	VASCULAR OCCLUSIVE EVENTS		0 4	ves	1				
a) Date of death		Disc	harged he	54. Pulmonary embolism diagnosed (circle one)		(NO) //		mar	20			
		a) (	06	A. Confirmed by radiological ex	mination (circle	YES	NO	lar	$IZ_{-}$	Mar		
day month	year		day	B. Date of pulmonary embolism diagnosis	dav	month	YEAT		1	166		
Fime of death			12 hours	55. Deep vein thrombosis diagnose (circle one)			f yes, must be confirm exc			21		
hours minutes	and and a	Tra b)	nsferred 1	A. Confirmed by ultrasound (cin	le ont]	YES	NO					
rimary cause of death /tick one of	nout only	b)	dey	B. Confirmed by radiological ex		YES	NO	Skip if Qb.				
ulmonary embolism		bi)		C. Date of deep vein thrombos	s							
epsis :her - d) Describe here:			hours	diagnosis	day	month	year					
		Stil	II in this F	56. Stroke diagnosed (circle one)	YES	NO	Yes only if new focal neur symptoms lastin	rological deficit with s g more than 24 hours	*			
		c)		A. New neuro			CARGE STREET, CO.	-			-	
ied, describe events leading to				57. Myocardial in A. ECG showin		- STATUS OF B		SCREENING ID NUMBER	after randomi	sation)		
TION E - MANAGEME	INT				aby	aby/ies - complete t	table below (Note: recorde			Vas baby	Suppler	betrac
Days in ICU (total)			Admiss to provi	B. History of t nu	nber Status -	after randomisation (circle one)	Cause of death (if applicable)	Any thromboem event in ba	bolic b	reastfed?	feed (circle	ng?
Any new infection since randomisation? (circle one)	YES	NO		C. Fatal case, v naked-eye a	Alive	Died after randomisation		YES	NO YE	5 NO	YES	NO
If yes to new infection – give details				recent coro (ante-morte 2 an atherom	Alive	Died after randomisation		YES	NO YE	5 NO	YES	NO
Antibiotic given? (circle one)	NO	FOR NEW INFECTION	FOR OMAN-2	one)	Alive	Died after		YES	NO YE	s NO	YES	NO
of Number: ISRC11402590155				D. Myocardial		randomisation						
0 Number: 15KC 1N02390133				diagnosis		PLETING DET	AILS - SECTIONS D	TO G				
0) Number: 15KC1162390133					Completed by (first name/last name	me)				5	Print name ch	ariy
0) Numpet: ISKC1062390133									Time			
of Number: ISKC (No2330133					Date completed		day month	68.	completed			
0) Number 15KL (1962396333				67.	Date completed		day month			l hou	173	minutes
oj Numder i SKL (19639933				67.	ignature		day month		completed	hou	13	minutes


Once all sections are completed, sign and date where indicated on CRF page 30

# OUTCOME FORM (Part 2): SECTION H

## WHEN: At 42 days following randomisation, discharge or death – whichever comes first

## **Patient Reported Outcomes (PRO)**

- Complete Sections H:
  - Observe the patient:
    - Are they short of breath?
    - Are they able to complete a questionnaire and/or 6 minute walk test?
  - If answer to H2 is 'a' or 'b', begin the PRO questionnaire (sections I K)



# **OUTCOME FORM (Part 2):** SECTIONS I - K

WHEN: At 42 days following randomisation, discharge or death – whichever comes first

## Patient Reported Outcomes (PRO): <u>questionnaire</u>

## What is the PRO questionnaire?

- The PRO questionnaire is a quality of life assessment tool.
- Each statement describes how people sometimes feel.
  - For each statement, the participant should say which answer best describes how they feel since giving birth.
- There are five possible answers to each statement



# **OUTCOME FORM (Part 2):** SECTIONS I - K

## **BEFORE STARTING THE QUESTIONNAIRE**

- Check the participant's medical records:
  - to determine whether question K8 is relevant (e.g. baby could have been a stillbirth or is requiring hospitalisation)
- Complete question H1 (this has to be completed before disturbing woman) then complete question H2
- Find a suitable location to administer the questionnaire
  - E.g. Somewhere reasonably quiet and where the woman would be comfortable
- Give some background information on the PRO (guidance available on CRF pg 31 and 32)

## **OUTCOME FORM (Part 2):** SECTIONS I - K

## **ADMINISTERING THE QUESTIONNAIRE**

- Ask the questions exactly as they appear in the CRF
- Always ask questions in a sensitive manner
- <u>Do not</u> provide your own examples for questions.
  - If a participant finds it difficult to understand a question, try to explain the concept of the question being asked. If the participant has provided examples, you may use these examples to help elicit an answer to the question



• <u>Do not</u> change answers to previously asked questions

# OUTCOME FORM (Part 2): SECTIONS L - M

#### WHEN: At 42 days following randomisation, discharge or death – whichever comes first

## Patient Reported Outcomes (PRO): <u>6 minute walk test</u>

#### What is the 6 minute walk-test?

- The 6 minute walk test is an assessment of exercise tolerance.
- Participants will be asked to walk between 2 cones, as many times as they can, for a period of 6 minutes.

#### Why the walk test for WOMAN-2?

• The walk test will show the impact of blood loss and give an indication of the woman's ability to carry out her daily physical activities after giving birth.

#### What will you need?

- 2 cones
- Tape Measure
- 1 or 2 chairs
- Blood Pressure Monitor
- Stopwatch



# OUTCOME FORM (Part 2): SECTIONS L - M

## WALK TEST - SET UP (1)

- Identify a straight area of walkway (e.g. a quiet corridor)
- Measure a distance between 10-30 metres and put the cones at either end as turning points
- The longer the distance the better to avoid participants having to make too many turns to minimise dizziness
- Have a chair (or 2) available to be given to the participant if she needs to stop and rest
- Ensure baby/(ies) is safely with family members, ward staff or in a cot where the mother can see him/her during the test
- Have water/other drinking fluid available
- Ensure help is available if needed during the walk test



## **OUTCOME FORM (Part 2):** SECTIONS L - M

## WALK TEST - SET UP (2)


• Check the woman's medical records and confirm with her:

#### Do not carry out the walk test if the woman has:

- A history of angina
- Had a myocardial infarction during the previous month
- Ensure appropriate pain relief has been given if required
- If participant uses walking aids (e.g. walking stick), have aid available
- If possible, use a wheelchair to bring the participant to the walk test area
- **Complete Section L** (participants perceived breathlessness)
- **Complete Section M1** (blood pressure, heart rate and respiratory rate)

#### A second person should be present during the walk test if the woman has a:

- Resting heart rate of greater than 120 bpm
- Systolic blood pressure of greater than 180 mmHg
- Diastolic blood pressure of greater than 100 mmHg
- Read the script on page 36 of the CRF
- Provide a demonstration of the walk test



## **OUTCOME FORM (Part 2 ): Section M**

### **CARRYING OUT THE WALK TEST**

- Use the stop watch to time 6 minutes
- If a participant usually uses a walking aid, they should use it for the walk test
- To encourage the participant, after each minute, tell the participant the following:
  - After the first minute, "You are doing well. You have 5 minutes to go."
  - After two minutes, "Keep up the good work. You have 4 minutes to go."
  - After three minutes, "You are doing well. You are halfway done."
  - After four minutes, "Keep up the good work. You have only 2 minutes left."
  - After five minutes, "You are doing well. You have only 1 minute to go."
- Do not use any other words of encouragement (or body language, to speed the participant up)
- Keep a tally of :
  - the number of times walked from one marker to the other
  - the number of times the participant stops to rest
- The walk test is for 6 minutes in total, even if the participant rests for most of the time
- When a participant stops to rest, please remind them at 1 minute intervals to continue walking of they can



# **OUTCOME FORM (Part 2 ): Section M**

#### **IMMEDIATELY AT THE END OF 6 MINUTES**

- Ask the participant to stop and stand still.
- Provide a chair if necessary
- If an incomplete length has been walked, mark where the participant stopped
- Complete Sections M3 and M6 immediately after walk test (Bp, HR, RR and breathlessness score)
- Complete the remainder of **Section M**

Read the following to We would like to mean You can see here marker	ire how far you can war	t in 6 millions	y times as you can.		f. Yotal distance walked in metres	the participant also walked a ontoin of the distance between rearbers, write the manheel of metrics the walked. Multiply lows M21 x M24. Then					
You can see two marker If you are tired or ward to	s here that I will ask you	to walk becaute of a	n you feel able.		M3. Please record immediately after wait test.						
				M3.	please record invited atory after walk	1442			122		
If you are bred or ware u I will show you what I wan								(beats per minute)			
			یر این چنز کر نایتا چاہئے ہیں کہ چو منٹ میں ای ان پیل در نشانات دیکو سکتی ہیں ہے۔ ا		b. Respiratory rate			Qureaths per mirs/he]			
		البون کی کدان کے در	ہر دن چر او جہ جاتے ہیں دو ہم میں ہے اپ بیان در نشانات دیکھ سکتی ہی میں اپ سے : اگر آپ تھاک جاتیں یا آرام کرنا چلیں تر دیٹھ سک		ptease record how many stops were	made during the					
Ustra .	ب جلس نقعہ جل سکتی <u>اور</u>	في الله جب أن الله	ی بیان او اگر آپ تھاک جائیں یا از ام کرنا جائیں تو تیٹھ سکا اپ کے اگرانے سے تیائے میں آپ کو دیکھکا چاہ	Mar. wee							
رع کار سکتی ہیں۔	موس کارین تو توبلزه شن با چاہلی یون،	نی ہوں کہ میں آپ سے کا	اپ کے کارنے سے تیشے علی اپ کو دیکھانا جاہ	M5. Please document reason(s) for stopping:							
DEMONSTRATION COMMENTA	ev owig is the minimum	m you are expected to	ser):		ise ask the participant immediately a				and the second		
Starting from here. Walk as fast	as you can to the next Keep walking, like I a	m doing now, staying o	e cone and back again, keeping as close as fose to the line until I say it is finished,	PERC	OVED BREATHLESSNESS POST TES		eittil A like ter ter اور (د) یکل		Nemos Line		
you can to the core and the inte- which will be at 6 minutes. Before the test, we would like to r				-	L have difficulty in breat		0 1	C			
Before the test, we would like to r	ecord your shown by the			N	ے سانس تینے میں مشکل پیش ۔ 16۔ ار ہی ہے	مجھے اس وہ	0 1	2	6		
Please record the following immed	fiately before test:		(mmHg)								
a, Blood pressure (systolic)		120		M7			ase give reasons (orda	(and)			
b. Blood pressure (diastolic)		90	[mmHg] [beats per minute]		a. Not applicable - walk test com b. Participant was not physically						
c. Heart rate		60	[breaths per minute]		c. Participant was physically well enough to try, but declined						
d. Respiratory rate	they at such sucressel but	IS	g the participant chooses to rest for most of the		d. Other (give reason):				4		
record six minute waik test bet			1								
Walk test start time	16:00 Nours	evitaliti									
alk test stop time	16	0 G									
tance between markers	20	-	[metres]								
nber of times walked from one to the other (complete	1411 144	r									
			W Version 1.2; Date 03 January 2019	,	rotocol Number: ISRCTN62396133		w	OMAN-2 CRF Booklet PAXISTAN Versio	2n 1.2; Date 0		
62396133	Page 38 of 43	Z CRF BOOKIET PAKOTA	11 11 11 11 11 11 11 11 11 11 11 11 11				Page 39 o	/ 43			
-	-		the state of the state								

If you have any concerns about the well-being of a participant, refer her back the treating clinician for further assessment and ongoing care

## **ADVERSE EVENT FORM**

(1) While participant is in hospital: record any <u>untoward</u> medical event that occurs up to 42 days after randomisation and is **NOT** collected on the outcome form

(2) After participant has been discharged from hospital: record any <u>untoward</u> medical event, which develops up to 42 days after randomisation (including those listed on the outcome forms)

- Record any Adverse Event immediately when it occurs (see Protocol for definition) on the Adverse Event CRF
- Complete all columns of each row
- Column B: SERIOUSNESS if any Adverse Event fulfils one or more of the 'seriousness' criteria, a Serious Adverse Event form (found in Investigator Study File, section 4) must also be completed

All adverse events must be uploaded to the trial database **within 24 hours of occurrence** 

					٨٢		RSE E		тс								
se t	his form to r	ecord any Adverse Event re	ported (	and not alr	eady c	ollect	ed as an o	utcome	e). See Protocol se	ection	3.15 and g	vidan	ice in fl	ne ISF			
A. 15	THE EVENT	B. SERIOUSNESS			C. REL	ATION:	SHIP TO	D. IF	NOT SUSPECTED (2)	) AT C, I	POSSIBLE	E. OU	TCOME	•			
DUE	то	1. Non-serious			TRIAL	TRIAL INTERVENTION			ERNATIVE CAUSE:				overed				
	GRESSION	Serious			(causa				asic disease/pre-exist	ting cor	dition			vith sequ			
	NDERLYING	2. Patient died					to be related		tercurrent disease					proving	it and unchanged		
	ESS?	3. Involved or prolonged in-patient hospitalisation 4. Results in persistent or significant				<ul> <li>if yes, provide reason why</li> <li>Not suspected to be</li> </ul>			3. Concomitant medication					teriorat			
L. Ye									4. Non-drug therapy/intervention			6. Dea	th				
2. No	)	disability/incapacity				related			5. Prior to randomisation								
		5. Life-threatening						6.0	6. Other non-drug cause, specify			*Only complete Column E and Date of					
6. Other, medically important													outcome on final review of patient/event				
		If 2-6 selected, comple	ete SAE fo	rm													
				Start da							Date of outcom				Person reporting		
AE		Adverse Event	A	start da even				D E		(if ongoing, )	- 1		ported	(full name)			
ID		Adverse Event A		(dd/mm/							blank)		(55),	(a			
				1							(dd/mm/y)	(vv)					
1																	
			_														
2																	
3																	
4																	
5												_					
			_														
6				1		1											

## **ALERT CARD**

• All participants should be given an **ALERT CARD at discharge** which contains information on who to contact if they develop any problems

<b>PRINCIPAL INVESTIGATOR:</b> Before discharge please fill in the details below and to the right, and then give this card to the woman	Please inform the	WOMAN WAS RANDOMISED INTO THE WOMAN-2 TRIAL. a Doctor or trial team member named below if she any medical problems within six weeks of date of randomisation.			
or her relative.	Doctor's name				
Name of participant	Telephone Trial team contact				
Randomisation number	Telephone				
Date of randomisation	Hospital				
	Address				
		The trial is sponsored and coordinated by a team at the University of London	ALERT CARD	woman2	
		Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK	Please keep this card with anyone giving you med	-	
		WOMAN2@LSHTM.AC.UK	If you require any medical six weeks of having your	baby, the doctor	
		Protocol number ISRCTN62396133	named overleaf must be informed.		

## **GENERAL GUIDANCE ON COMPLETING THE CRF BOOKLET**

- All data contained in the CRF booklet <u>must</u> be recorded in the medical records
  - If trial data is *not* available in the medical records but has been obtained by speaking with the trial participant or the clinical team, record this in the medical records if allowed.
  - Otherwise, record this data in the WOMAN-2 communication logbook
- CRF completion and database entry can be delegated to a trained trial team member by the Principal Investigator (PI). The PI retains overall responsibility
- The PI should review and sign each **completed** CRF booklet




## **GENERAL GUIDANCE ON COMPLETING THE CRF BOOKLET**

- Each page in the CRF booklet has guidance for completion. Review this guidance carefully
- Use black or blue ink pen with clear, legible handwriting throughout
- Ensure all applicable fields have been completed

#### IF YOU ENTER AN INCORRECT VALUE ON THE FORM:


- Do NOT use correction fluid
- Cross out the incorrect value so it is still visible
- Enter the correct value alongside
- Date and initial and provide a reason for **each** change



# FOR FURTHER GUIDANCE SEE:

## The Trial Procedures File, section 7:

- 7.1 Documenting trial data in participant medical records
- 7.2 What data to collect and when
- 7.3 CRF completion and database entry guidelines
- 7.4 How to administer the Participant Reported Outcome Questionnaire
- 7.5 How to administer the breathlessness test and 6 minute walk test





Clinical Trials Unit London School of Hygiene & Tropical Medicine Keppel Street, London WC1E 7HT

> Tel: +44(0)20 7299 4684 Email: woman2@Lshtm.ac.uk Website: woman2.Lshtm.ac.uk



